OncoMatch/Clinical Trials/NCT06507618
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Is NCT06507618 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Tamoxifen, Letrozole, Anastrozole, or Exemestane for breast cancer female.
Treatment: Tamoxifen, Letrozole, Anastrozole, or Exemestane — This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery. Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (positive)
ER+
Required: PR (PGR) overexpression (+/-)
PR +/-
Required: HER2 (ERBB2) non amplified (negative)
HER2- non amplified
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: endocrine therapy (tamoxifen, aromatase inhibitor)
Prior use of Tamoxifen or aromatase inhibitors
Cannot have received: radiation therapy
History of ipsilateral breast radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia · Charlottesville, Virginia
- University of Virginia Community Health · Culpeper, Virginia
- INOVA Schar Cancer · Fairfax, Virginia
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06507618 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior endocrine therapy, radiation therapy disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 overexpression is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 non amplified is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify